Schedule 2 to the Principal Order is amended as follows:

(a) by omitting item 2011M and substituting the following:

2011M.

Beclomethasone in aqueous nasal sprays delivering 50 micrograms or less of beclomethasone per actuation, when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

(b) by omitting item 2019M and substituting the following:

2019M.

Budesonide in aqueous nasal sprays delivering 50 micrograms or less of budesonide per actuation, when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

(c) by omitting item 2027 and substituting the following:

2027.

Ciclopirox in preparations for dermal use containing 2% or less of ciclopirox except in preparations for dermal use for the treatment of tinea pedis.

(d) by omitting item 2038 ;

(e) by omitting item 2054 and substituting the following:

2054.	Fluorides for human use (except in preparations containing 15mg/kg or 15mg/L or less of fluoride ion) –
	(a) as sodium fluoride, in preparations for ingestion containing 2.2mg or less of sodium fluoride per dosage unit; or
	(b) in preparations for topical use containing 2.5% or less of fluoride ion except –
	(i) when included in Schedule 3 ; or
	(ii) dental hygiene, whitening or bleaching products that are pastes, powders or gels for use on teeth, containing 1 000mg/kg or less of fluoride ion; or
	(iii) other dental hygiene, whitening or bleaching products that are therapeutic goods, containing 220mg/kg or 220mg/L or less of fluoride ion, in packs containing not more than 120mg total fluoride, fitted with a child-resistant closure, when compliant with the requirements of the Required Advisory Statements for Medicine Labels ; or
	(iv) other dental hygiene, whitening or bleaching products that are not therapeutic goods, containing 220mg/kg or 220mg/L or less of fluoride ion, in packs containing not more than 120mg total fluoride, fitted with a child-resistant closure and labelled with warnings to the following effect:
	(A)  Do not swallow;
	(B)  Do not use [this product / name of product] in children 6 years of age or less.

(f) by omitting item 2054J and substituting the following:

2054J.

Fluticasone in aqueous nasal sprays delivering 50 micrograms or less of fluticasone per actuation, when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

(g) by omitting item 2081 and substituting the following:

2081.	Lithium in preparations for dermal use containing 1% or less of lithium except –
	(a) when present as an excipient at 0.25% or less of lithium; or
	(b) in preparations containing 0.01% or less of lithium.

(h) by omitting item 2089 ;

(i) by omitting item 2127 and substituting the following:

2127.	Silver for therapeutic use except –
	(a) in solutions for human oral use containing 0.3% or less of silver when compliant with the requirements of the Required Advisory Statements for Medicine Labels ; or
	(b) in other preparations containing 1% or less of silver.

(j) by omitting item 2133 and substituting the following:

2133.

Terbinafine for dermal use except in preparations for the treatment of tinea pedis.

(k) by omitting item 2139M and substituting the following:

2139M.

Triamcinolone in aqueous nasal sprays delivering 55 micrograms or less of triamcinolone per actuation, when the maximum recommended daily dose is no greater than 220 micrograms, for prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.